[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350096-105":59,"doc-detail-350096-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","inhibition-of-cdk9-sensitizes-multidrug-resistant-ovarian-cancer-cells-to-paclitaxel","Inhibition of CDK9 sensitizes multidrug resistant ovarian cancer cells to paclitaxel","","Multidrug resistance drives treatment failure in ovarian cancer, and CDK9 overexpression has been linked to tumor transcriptional regulation, yet its contribution to ovarian drug resistance is unclear. Expression of CDK9 and related proteins was examined in paired drug-resistant and parental drug-sensitive ovarian cancer cell lines. CDK9 was higher in resistant cells, while CDK9 suppression via siRNA or LDC067 increased paclitaxel sensitivity by reducing RNA polymerase II and Stat3 phosphorylation, promoting apoptosis, and impairing spheroid formation and motility.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/inhibition-of-cdk9-sensitizes-multidrug-resistant-ovarian-cancer-cells-to-paclitaxel/350096/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/inhibition-of-cdk9-sensitizes-multidrug-resistant-ovarian-cancer-cells-to-paclitaxel/350096.png","ImageObject",300,407,{"name":92,"@type":93},"Sophia Brooks","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is multidrug resistance a major problem in ovarian cancer treatment?","Question",{"text":112,"@type":113},"Most ovarian cancer patients initially responsive to paclitaxel develop broad cross-resistance, limiting chemotherapy success and contributing to relapse or death due to resistant or metastatic disease.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What relationship between CDK9 and drug resistance was observed in ovarian cancer cells?",{"text":117,"@type":113},"Both drug-resistant ovarian cancer cell lines showed higher CDK9 expression compared with their parental drug-sensitive counterparts.",{"name":119,"@type":110,"acceptedAnswer":120},"How does inhibiting CDK9 affect paclitaxel sensitivity and cell behavior?",{"text":121,"@type":113},"CDK9 inhibition, using siRNA or the CDK9 inhibitor LDC067, enhanced paclitaxel sensitivity, reduced phosphorylation of RNA polymerase II and Stat3, increased apoptosis, and decreased spheroid formation and cell motility.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350096,1790301083,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nInhibition ofCDK9 sensitizes multidrug resistant ovarian cancer cells to paclitaxel  \nJinglu Wang1, Francis J. Hornicek2, Huirong Shi1, Wenlong Feng1􀀍 & Zhenfeng Duan2,3􀀍  \nMultidrug resistance is the major cause of treatment failure in ovarian cancer. Overexpression of cyclin-dependent kinase (CDK) 9 has been observed in a variety of cancers and promotes tumor cell growth and proliferation by regulating transcription. However, the role ofCDK9 in drug resistance of ovarian cancer remains unknown. In this study, the expression levels ofCDK9 and related proteins were evaluated in two pairs of human ovarian cancer drug-resistant cell lines by western blot. We found that both drug resistant ovarian cancer cells expressed higher levels ofCDK9 as compared with their parental drug sensitive cell lines. Additionally, inhibition ofCDK9, with either siRNA or a CDK9 inhibitor LDC067, enhanced paclitaxel sensitivity in drug resistant ovarian cancer cells. This was also accompanied with a reduction in the phosphorylation of RNA polymerase II and Stat3, resulting in enhanced apoptosis. Furthermore, inhibition ofCDK9 also decreased ovarian cancer spheroid formation and cell motility. These findings collectively indicate that inhibition ofCDK9 can enhance paclitaxel sensitivity in drug resistant ovarian cancer cells by increasing apoptosis. CDK9 represents a promising target for overcome drug resistance in ovarian cancer.  \nKeywords Ovarian cancer, CDK9, LDC000067/LDC067, Drug resistance, Transcription, Apoptosis  \nAbbreviations  \nCDK9 cyclin-dependent kinase 9 MDR multidrug resistance  \nLDC067 LDC000067  \nRNAPII RNA polymerase II  \nMTT Methyl thiazolyl tetrazolium  \nCI combination index  \n3D Three-dimensional (3D)  \nOvarian cancer is the sixth-leading cause of cancer death among women and the deadliest of gynecologic cancers because it is often diagnosed at an advanced stage1. The American Cancer Society estimates that approximately 20,890 new ovarian cancer cases and 12,730 deaths will occur in the United States in 2025 alone1. Despite the advances in surgical techniques and chemotherapy drugs for several decades, the overall 5-year survival rate of ovarian cancer patients increased slightly from 36% in 1975 to 51% in 20201,2. Currently, the microtubule stabilizing based chemotherapy agent paclitaxel (trade name Taxol) is widely used in the clinical treatment of ovarian cancer in combination with cisplatin (or carboplatin) . However, most ovarian cancer patients who are initially responsive to paclitaxel will inevitably develop broad cross resistance (multidrug resistance, MDR) that can include a variety of structurally and functionally unrelated chemotherapeutic agents3. MDR is a major clinical problem that severely limits the success rate of chemotherapy in ovarian cancer treatment, leading to patient relapse or even death due to drug resistant/metastatic disease4. Therefore, therapeutic exploitation of more potent agents to sensitize MDR cells to chemotherapy is essential to improve the clinical outcome of ovarian cancer.  \n1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, 1 Jianshe East Road, Zhengzhou 450052, Henan, China. 2Department of Orthopedic Surgery, Sarcoma Biology Laboratory, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Papanicolaou Cancer Research Building, 1550 NW. 10th Avenue, Miami, FL 33136, USA. 3Department of Orthopedic Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, United States of American, Papanicolaou Cancer Research Building, 1550 NW. 10th Avenue, Miami, FL 33136, USA. 􀀍 email: [fccfengwl@zzu.edu.cn](fccfengwl@zzu.edu.cn); [zxd221@med.miami.edu](zxd221@med.miami.edu)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nCyclin-dependent kinases (CDKs) are members of the serine/thr","cbCaifbqJv9ldgoi","https://ap.wps.com/l/cbCaifbqJv9ldgoi","pdf",2074905,12,"English","# Background\n## Ovarian cancer burden and multidrug resistance\n## Paclitaxel use and the emergence of MDR\n# Rationale for CDK9 targeting\n## CDKs in transcription and cell-cycle regulation\n## CDK9 as a therapeutic candidate\n# Study objective and experimental approach\n## Comparing resistant and parental cell lines","[{\"question\":\"Why is multidrug resistance a major problem in ovarian cancer treatment?\",\"answer\":\"Most ovarian cancer patients initially responsive to paclitaxel develop broad cross-resistance, limiting chemotherapy success and contributing to relapse or death due to resistant or metastatic disease.\"},{\"question\":\"What relationship between CDK9 and drug resistance was observed in ovarian cancer cells?\",\"answer\":\"Both drug-resistant ovarian cancer cell lines showed higher CDK9 expression compared with their parental drug-sensitive counterparts.\"},{\"question\":\"How does inhibiting CDK9 affect paclitaxel sensitivity and cell behavior?\",\"answer\":\"CDK9 inhibition, using siRNA or the CDK9 inhibitor LDC067, enhanced paclitaxel sensitivity, reduced phosphorylation of RNA polymerase II and Stat3, increased apoptosis, and decreased spheroid formation and cell motility.\"}]","Inhibition of CDK9 sensitizes multidrug resistant ovarian cancer cells to paclitaxel | PDF",1790087149,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/107675d3b278f2b8e4b261ef2a8b2da4.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1dc68dfe5dd8a6ec5817ac838bc4e63e.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/855b455ddcfe0bbb1dd2890b8bf0cd05.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/477e8b2f7a010ecf5c46c3213016f590.webp",980,1287]